Table 3:

Best responses to elotuzumab plus lenalidomide and dexamethasone in the intention-to-treat population

	Elotuzumab 10 mg/kg (n=36)	Elotuzumab 20 mg/kg (n=37)	Total (N=73)
Overall response*	33 (92%), 77·5–98·2	28 (76%), 58·8–88·2	61 (84%), 73·0–91·2
Best confirmed response†
Stringent complete response	2 (6%)	1 (3%)	3 (4%)
Complete response	4 (11%)	3 (8%)	7 (10%)
Very good partial response	17 (47%)	14 (38%)	31 (42%)
Partial response	10 (28%)	10 (27%)	20 (27%)
Stable disease	3 (8%)	7 (19%)	10 (14%)
Missing	0	2 (5%)	2 (3%)

Data are n (%), 95% CI. Responses were graded according to International Myeloma Working Group criteria.

^*Overall responses comprised stringent complete response, complete response, very good partial response, and partial response.

^†Confirmed responses required two or more consecutive assessments of the same response.